{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T05:01:54Z","timestamp":1782363714708,"version":"3.54.5"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"26","license":[{"start":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T00:00:00Z","timestamp":1593129600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>The potential benefits and safety of hepatic arterial infusion chemotherapy (HAIC) for the treatment of patients with hepatocellular carcinoma (HCC) remains inconsistent. Therefore, we conducted this meta-analysis of evaluate the efficacy and safety of HAIC in the treatment of HCC.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A comprehensive literature search was performed using PubMed, Embase, Web of Science, and the Cochrane library to identify eligible studies that compared HAIC with other therapies for patients with HCC. The main outcomes of our interest, including overall survival (OS), disease free survival (DFS), objective response rate (ORR), disease control rate (DCR), and adverse events, were calculated using the meta-analysis. The pooled estimates were expressed with hazard ratio (HR) with 95%confidence intervals (95%CIs) or risk ratio (RR) with 95%CIs.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>A total of 13 studies met the inclusion criteria and were included in this meta-analysis. Pooled estimates showed that, HAIC was associated with significantly improved OS (HR\u200a=\u200a0.61, 95%CI: 0.48, 0.77; <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.001) and DFS (HR\u200a=\u200a0.66, 95%CI: 0.52, 0.84; <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.001) as compared with other therapies. The ORR (RR\u200a=\u200a2.28, 95%CI: 1.77, 2.94; <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.001) and DCR (RR\u200a=\u200a1.47, 95%CI: 1.23, 1.77; <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.001) were also significantly higher in HAIC group than in control group. Most of the common adverse events were comparably occurred in the 2 groups, except for nausea\/vomiting, hypoalbuminemia, pain, anemia and hepatic toxicity. Subgroup analysis suggested that, the improved OS and DFS associated with HAIC were only observed in patients with colorectal liver metastases (CRLM), or advanced HCC, but not in those with unresectable HCC or pancreatic liver metastases.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Based on the present data, HAIC showed benefit effect in HCC patients, with pronged OS and DFS, as well as increased ORR and DCR. These benefit effects were more obvious in CRLM or advanced HCC patients. However, considering the potential limitations, more large-scale, randomized trials are needed to verify our findings.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000020745","type":"journal-article","created":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T18:41:29Z","timestamp":1592937689000},"page":"e20745","source":"Crossref","is-referenced-by-count":15,"title":["Effects of hepatic arterial infusion chemotherapy in the treatment of hepatocellular carcinoma"],"prefix":"10.1097","volume":"99","author":[{"given":"Guan-Bao","family":"Long","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-Wen","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Yang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,6,26]]},"reference":[{"key":"R1-20230915","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"R2-20230915","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/ijc.1440","article-title":"Estimating the world cancer burden: Globocan 2000","author":"Parkin","year":"2001","journal-title":"Int J Cancer V 94"},{"key":"R3-20230915","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1159\/000449346","article-title":"Hepatocellular carcinoma: the role of interventional oncology","volume":"6","author":"Donadon","year":"2016","journal-title":"Liver Cancer"},{"key":"R4-20230915","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000449347","article-title":"Transarterial therapies for hepatocellular carcinoma","volume":"6","author":"Lanza","year":"2016","journal-title":"Liver Cancer"},{"key":"R5-20230915","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1159\/000367775","article-title":"Survival analysis over 28 years of 173,378 patients with hepatocellular carcinoma in Japan","volume":"5","author":"Kudo","year":"2016","journal-title":"Liver Cancer"},{"key":"R6-20230915","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1634\/theoncologist.2012-0121","article-title":"The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus","volume":"17","author":"Adam","year":"2012","journal-title":"Oncologist"},{"key":"R7-20230915","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1053\/j.gastro.2015.12.041","article-title":"Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma","volume":"150","author":"Bruix","year":"2016","journal-title":"Gastroenterology"},{"key":"R8-20230915","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1159\/000449343","article-title":"Hepatocellular carcinoma: therapeutic guidelines and medical treatment","volume":"6","author":"Kudo","year":"2016","journal-title":"Liver Cancer"},{"key":"R9-20230915","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/cncr.10694","article-title":"Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases","volume":"95","author":"Ando","year":"2002","journal-title":"Cancer"},{"key":"R10-20230915","doi-asserted-by":"crossref","first-page":"3426","DOI":"10.3748\/wjg.v18.i26.3426","article-title":"Efficacy of hepatic arterial infusion chemotherapy in advanced hepatocellular carcinoma","volume":"18","author":"Baek","year":"2012","journal-title":"World J Gastroenterol"},{"key":"R11-20230915","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1200\/JCO.2005.03.8166","article-title":"Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (calgb 9481)","volume":"24","author":"Kemeny","year":"2006","journal-title":"J Clin Oncol"},{"key":"R12-20230915","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1067\/msy.2002.122374","article-title":"Downstaging of hepatocellular carcinoma and liver metastases from colorectal cancer by selective intra-arterial chemotherapy","volume":"131","author":"Clavien","year":"2002","journal-title":"Surgery"},{"key":"R13-20230915","first-page":"495","article-title":"Downstaging followed by resection plays a role in improving prognosis of unresectable hepatocellular carcinoma","volume":"3","author":"Tang","year":"2004","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"R14-20230915","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1093\/jnci\/88.5.252","article-title":"Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer","volume":"88","author":"Piedbois","year":"1996","journal-title":"J Natl Cancer Inst"},{"key":"R15-20230915","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ (Clinical research ed)"},{"key":"R17-20230915","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The cochrane collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ (Clinical research ed)"},{"key":"R18-20230915","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ (Clinical research ed)"},{"key":"R19-20230915","first-page":"719","article-title":"Statistical aspects of the analysis of data from retrospective studies of disease","volume":"22","author":"Mantel","year":"1959","journal-title":"J Natl Cancer Inst"},{"key":"R20-20230915","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"R21-20230915","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ (clinical research ed)"},{"key":"R22-20230915","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","volume":"50","author":"Begg","year":"1994","journal-title":"Biometrics"},{"key":"R23-20230915","first-page":"4747","article-title":"Low-dose leucovorin and 5-fluorouracil for unresectable multiple liver metastasis from colorectal cancer","volume":"25","author":"Ishibashi","year":"2005","journal-title":"Anticancer Res"},{"key":"R24-20230915","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1186\/s12885-017-3320-7","article-title":"Transhepatic arterial infusion chemotherapy using a combination of miriplatin and CDDP powder versus miriplatin alone in the treatment of hepatocellular carcinoma: a randomized controlled trial","volume":"17","author":"Kamimura","year":"2017","journal-title":"BMC Cancer"},{"key":"R25-20230915","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s40880-017-0251-2","article-title":"Hepatic artery infusion chemotherapy using mfolfox versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study","volume":"36","author":"He","year":"2017","journal-title":"Chin J Cancer"},{"key":"R26-20230915","first-page":"1087","article-title":"Prophylactic adjuvant hepatic arterial infusion chemotherapy reduced hepatic metastases from stage III colorectal cancer after curative resection","volume":"59","author":"Feng","year":"2012","journal-title":"Hepatogastroenterology"},{"key":"R27-20230915","first-page":"1415","article-title":"Hepatic arterial infusion chemotherapy reduced hepatic metastases from pancreatic cancer after pancreatectomy","volume":"61","author":"Zheng","year":"2014","journal-title":"Hepatogastroenterology"},{"key":"R28-20230915","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/j.1743-7563.2012.01543.x","article-title":"The efficacy of hepatic arterial infusion chemotherapy as an alternative to sorafenib in advanced hepatocellular carcinoma","volume":"8","author":"Jeong","year":"2012","journal-title":"Asia Pac J Clin Oncol"},{"key":"R29-20230915","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S2468-1253(18)30078-5","article-title":"Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (silius): a randomised, open label, phase 3 trial","volume":"3","author":"Kudo","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R30-20230915","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0748-7983(03)00002-7","article-title":"A comparison between hepatic artery ligation and portal 5-FU infusion versus 5-FU intra arterial infusion for colorectal liver metastases","author":"Naredi","year":"2003","journal-title":"Eur J Surg Oncol V 29"},{"key":"R31-20230915","doi-asserted-by":"crossref","first-page":"10443","DOI":"10.3748\/wjg.v21.i36.10443","article-title":"Chemoembolization alone vs combined chemoembolization and hepatic arterial infusion chemotherapy in inoperable hepatocellular carcinoma patients","volume":"21","author":"Gao","year":"2015","journal-title":"World J Gastroenterol"},{"key":"R32-20230915","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1245\/s10434-010-1505-2","article-title":"Selective intra-arterial chemotherapy with floxuridine as second- or third-line approach in patients with unresectable colorectal liver metastases","volume":"18","author":"Samaras","year":"2011","journal-title":"Ann Surg Oncol"},{"key":"R33-20230915","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1038\/bjc.2013.542","article-title":"Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the nationwide survey of primary liver cancer in Japan","volume":"109","author":"Nouso","year":"2013","journal-title":"Br J Cancer"},{"key":"R34-20230915","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1159\/000473887","article-title":"Sorafenib versus hepatic arterial infusion chemotherapy as initial treatment for hepatocellular carcinoma with advanced portal vein tumor thrombosis","volume":"6","author":"Moriguchi","year":"2017","journal-title":"Liver Cancer"},{"key":"R35-20230915","doi-asserted-by":"crossref","first-page":"141590","DOI":"10.1155\/2013\/141590","article-title":"Modern prospection for hepatic arterial infusion chemotherapy in malignancies with liver metastases","volume":"2013","author":"Liang","year":"2013","journal-title":"Int J Hepatol"},{"key":"R36-20230915","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1007\/s00595-012-0416-1","article-title":"Clinical significance of and future perspectives for hepatic arterial infusion chemotherapy in patients with liver metastases from colorectal cancer","volume":"43","author":"Sadahiro","year":"2013","journal-title":"Surg today"},{"key":"R37-20230915","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/S0140-6736(03)12388-4","article-title":"Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trial","volume":"361","author":"Kerr","year":"2003","journal-title":"Lancet (London, England)"},{"key":"R38-20230915","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1002\/jso.21753","article-title":"Role of intra-arterial hepatic chemotherapy in the treatment of colorectal cancer metastases","volume":"102","author":"Kingham","year":"2010","journal-title":"J Surg Oncol"},{"key":"R39-20230915","doi-asserted-by":"crossref","first-page":"4881","DOI":"10.1200\/JCO.2005.05.120","article-title":"Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale Des Centres De Lutte Contre Le Cancer","volume":"23","author":"Ducreux","year":"2005","journal-title":"J Clin Oncol"},{"key":"R40-20230915","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1245\/s10434-007-9581-7","article-title":"Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure","volume":"15","author":"Boige","year":"2008","journal-title":"Ann Surg Oncol"},{"key":"R41-20230915","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1023\/A:1011186708754","article-title":"Phase I and pharmacokinetic study of hepatic arterial infusion with oxaliplatin in combination with folinic acid and 5-fluorouracil in patients with hepatic metastases from colorectal cancer","volume":"12","author":"Kern","year":"2001","journal-title":"Ann Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000020745","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T00:21:28Z","timestamp":1694823688000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000020745"}},"subtitle":["A meta-analysis"],"short-title":[],"issued":{"date-parts":[[2020,6,26]]},"references-count":40,"journal-issue":{"issue":"26","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000020745","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,26]]}}}